References
- Rzany B, Mockenhaupt M, Stocker U, Hamouda O, Schopf E. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol 1993; 129: 1059.
- Teira R, Virosta M, Zubero Z, Muñoz J, Santamaría JM. The safety of pyrimethamine-sulfadoxine for the prophylaxis of Pneumocystis carinii pneumonia in patients infected with HIV. Scan J Infect Dis 1997; 29: 595–6.
- Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977; 21: 247–54.
- Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti C, Shapiro S, Shear N, Schopf E, Kaufman DW. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–7.
- Fazal BA, Turett GS, Justman JE, Hall G, Telzak EE. Stevens-Johnson syndrome induced by treatment with acyclovir. Clin Infect Dis 1995; 21: 1038–9.
- Parneix-Spake A, Bastuji-Garin S, Levy Y, Dubreuil-Lemaire ML, Roujeau JC. Didanosine as probable cause of StevensJohnson syndrome. Lancet 1992; 340: 857–8.